Obsidian Therapeutics, Inc. — Form S-1
Filed August 28, 2026 · analyzed by the Registration Agent
S-1
— Neutral
significance 42/100
What the filing says
Obsidian Therapeutics, a Delaware biotech corporation, filed a Form S-1 registration statement on August 28, 2026, to register up to 29,164,045 shares of common stock ($0.0001 par value) for sale by existing shareholders. This is a primary public offering by selling stockholders; no IPO pricing or use-of-proceeds details are disclosed in this exhibit package. The company operates through subsidiaries including Galera Therapeutics, Inc. (DE) and Nova Pharmaceuticals Operating, LLC (DE), among others.
Why this rating
S-1 filing is standard IPO documentation; no financial metrics, valuation, or pricing disclosed here to assess impact magnitude relative to company size.
See more from August 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.